Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

approvedOpamtistomigPositive

AI Analysis

Summary

Leads Biolabs received NMPA approval for an IND application to conduct a Phase Ib/II clinical trial of its PD-L1/4-1BB bispecific antibody Opamtistomig in combination therapy for metastatic colorectal cancer. The approval expands the company's gastrointestinal oncology franchise into colorectal cancer indications.

Clinical Trial Data

Phase

Ib/II

Outcome Details

IND application approved by NMPA's Center for Drug Evaluation for Phase Ib/II clinical trial

Importance:6/10

Sentiment:

0.75

immuno-oncologybispecific antibodycolorectal cancergastrointestinal oncologyChinaNMPA approvalcombination therapy

Related Companies

$POAI $NHC $DFPH $MDCE $CHHE

Read the original article

Published by GlobeNewswire Clinical Studies on August 3, 2026 3:43 AM

Read Original